Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America Healthy Again Commission (MAHA). 17 March 2025
The UK government plans to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' National Health Service (NHS) sales in the second half of 2025. 14 March 2025
Regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the ABPI Code of Practice has come to an end. 17 March 2025
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
California commercial-stage biopharma firm Geron Corporation has announced that Dr John “Chip” Scarlett, president, chief executive (CEO) and chairman, will depart the company on March 31, 2025. 12 March 2025
The UK government has announced the appointment of Lawrence Tallon as the new chief executive (CEO) of the Medicines and Healthcare products Regulatory Agency (MHRA). 4 March 2025